Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a cumulative rise of over 500% since July 14, and a current price of 11.95 HKD, reflecting a 19.5% increase at the time of reporting [1] Group 1: Strategic Developments - On August 8, Huajian Medical announced the launch of its "Global Enhanced Ethereum (ETH) Treasury" strategy and formed a global strategic partnership with HashKey Group [1] - A signing ceremony for the global strategic cooperation and the upgrade of the Global Enhanced Ethereum (ETH) Treasury strategy was held on August 11 at HashKey's office in Hong Kong [1] Group 2: Collaborations and Investments - On July 30, Huajian Medical signed a strategic cooperation framework agreement with BGI Win to establish the "Huajian BGI Win Innovative Drug Intellectual Property Tokenization Fund" [1] - This fund aims to invest in Huajian Medical's "NewCo+RWA" Web3 exchange ecosystem projects in Hong Kong, the United States, and other locations [1] - BGI Win, initiated by BGI Genomics, is a corporate venture capital entity with extensive experience and resources in innovative medical and pharmaceutical investments [1]

Core Insights - Huajian Medical (01931) has signed a strategic cooperation framework agreement with BGI CoWin to establish the "Huajian-BGI CoWin Innovative Drug Intellectual Property Tokenization Fund" aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6][7] - Following the announcement, Huajian Medical's stock price surged by 15.78%, nearing HKD 5 per share, with a market capitalization reaching HKD 8 billion [3][6] - The fund will address long-standing industry challenges by tokenizing high-value medical assets, allowing ordinary investors access to clinical-stage drug development [6][10] Group 1: Fund Structure and Strategy - The framework agreement outlines that Huajian Medical or its designated entity will act as a limited partner, while BGI CoWin will serve as the general partner responsible for fund management [7] - The fund aims to leverage BGI CoWin's resources in innovative medical projects to select high-quality targets for investment [7][9] - The establishment of the fund coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7][10] Group 2: Web3 Ecosystem Development - The fund represents a key component of Huajian Medical's "NewCo + RWA + Stablecoin" strategy, which aims to reshape the global value chain of innovative drug assets [8][9] - BGI CoWin will provide comprehensive services from due diligence to transaction design for selected pharmaceutical companies or target assets [9] - Huajian Medical has registered a wholly-owned subsidiary in New York and is applying for stablecoin licenses, positioning itself advantageously in the regulatory landscape [9][10] Group 3: Market Potential and Innovation - The global RWA market is projected to reach USD 16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [10][11] - The traditional pharmaceutical R&D model faces liquidity challenges, with 80% of funding consumed during clinical stages, excluding ordinary investors [10][11] - Huajian Medical's strategy focuses on the medical innovation drug sector, aiming to create a "global free trading market" for innovative drug assets through its three-tiered structure [10][11] Group 4: Brand Transformation - Huajian Medical announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [12][13] - The new logo symbolizes the company's vision of transforming from a medical device distributor to a builder of a decentralized scientific ecosystem [12][13] - The ultimate goal is to enable top-tier medical innovative drug IP to circulate freely like digital currency, creating a positive cycle among capital, R&D, and commercialization [12][13]

Core Viewpoint - 华检医疗 has signed a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金," aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6]. Group 1: Fund Establishment and Market Context - The newly established fund will be managed by 华大共赢, which will act as the general partner, while 华检医疗 will contribute as a limited partner [7]. - The fund's creation coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7]. - The innovative drug sector has become a hot investment area, with the 中证港股通创新药指数 increasing by over 124% since the beginning of the year [7]. Group 2: Web3 Strategy and Ecosystem - The fund represents a key component of 华检医疗's "NewCo+RWA+stablecoin" strategy, which aims to reshape the global medical innovation drug asset value chain [9]. - 华大共赢 will provide comprehensive services from due diligence to transaction design for selected innovative pharmaceutical companies or target assets [9]. - The ecosystem includes the "IVDNewCo Exchange" trading platform and the proprietary stablecoin IVD Dollar (IVDD), with regulatory applications already initiated in the US and Hong Kong [9][10]. Group 3: Market Potential and Value Chain Reconstruction - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [11]. - The traditional pharmaceutical R&D model faces liquidity issues, with 80% of funding consumed during clinical phases, excluding ordinary investors [11]. - 华检医疗's approach focuses on the medical innovation drug sector, aiming to create a "global free trading market" through its three-tiered structure [11][12]. Group 4: Brand Transformation - 华检医疗 announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [13][14]. - The new logo symbolizes the company's vision of enabling top medical innovation drug IP to circulate freely like digital currency [14][15].

Group 1 - The company has entered into a strategic cooperation framework agreement with BGI CoWin to establish an innovative drug intellectual property tokenization fund [1] - The fund will invest in projects under the NewCo+RWA Web3 exchange ecosystem model in Hong Kong, the United States, or other overseas regions [1] - BGI CoWin will act as the general partner responsible for managing the NewCo innovative drug RWA fund, while the company will contribute as a limited partner [1] Group 2 - The strategic cooperation aims to enhance the company's business layout through a tripartite strategy of "NewCo+RWA+stablecoin" [2] - This collaboration is expected to strengthen the company's role in reshaping the global medical innovative drug asset value chain [2]